II | Jotup

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Retrieved on:

星期一, 四月 22, 2024

FDA, Patient, Dexmedetomidine, Safety, Agitation, Food, Bipolar disorder, Intermittent explosive disorder, Intelligence, Schizophrenia, Medicine, New product development, DSM-IV codes, Therapy, Type, Pharmaceutical industry

NEW HAVEN, Conn., April 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced additional details regarding the planned design of its SERENITY At-Home Phase 3 trial*to evaluate BXCL501, the Company’s investigational, proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with bipolar disorders or schizophrenia in the home setting. The Company’s plan to conduct this trial using a 120 mcg dose is based on feedback received from the U.S. Food and Drug Administration (FDA) following the recent receipt of agency minutes from the Type C meeting held on March 6, 2024.

Key Points:

The outpatient trial is expected to enroll a total of approximately 200 patients with agitation associated with bipolar disorder or schizophrenia.
Patients will self-administer 120 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.
The primary objective is safety with efficacy measures as exploratory endpoints to evaluate use in the outpatient setting.
A corporate presentation, including information on the SERENITY program, is available on the Investors section of the Company’s website: bioxceltherapeutics.com.

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on:

星期四, 四月 18, 2024

American Academy, University, Participation, MD, Research, Publication, Patient, RMS, AAN, USF, Sclerosis, Multiple sclerosis, Poster, Therapy, Pharmaceutical industry

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.

Key Points:

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
Links to the data presented yesterday are included below.
Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The data presented this week during the AAN annual meeting emphasizes our commitment to research and the multiple sclerosis community.
We look forward to continuing to evaluate date from the ULTIMATE Phase 3 trials and presenting additional exploratory data throughout the year.”
Link to Poster Presentation: Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies
Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
All data presented at AAN is also available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

Vallourec progresses its holistic balance sheet refinancing with successful pricing of its 2032 Senior Notes offering

Retrieved on:

星期四, 四月 18, 2024

Sale, Prospectus, Person, Investment, Nature, RCF, EEA, Finance, FSMA, S&P, Environment, Senior, Vallourec, Order, Financial services, PGE, Security (finance)

The offering of the Notes is expected to close on April 23, 2024, subject to customary closing conditions.

Key Points:

The offering of the Notes is expected to close on April 23, 2024, subject to customary closing conditions.
Philippe Guillemot, Chairman of the Board of Directors, and Chief Executive Officer, declared: “I am extremely pleased with the results of this transaction and our overall balance sheet refinancing.
This step further strengthens Vallourec's financial position and sustainably improves its cash flow generation.
The completion of this transaction will give us both greater visibility and financial flexibility over the coming years.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Retrieved on:

星期二, 四月 16, 2024

Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health.

Key Points:

Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health.
“I am excited to see how balanced and healthy our pipeline looks today,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
To support the company’s growth, Boehringer announced a 5-year, EUR 7 billion capital investment plan last year.
For 2024, Boehringer Ingelheim expects a slight year-on-year increase in revenues on a comparable basis, adjusted for currency and extraordinary effects.

Vallourec announces an offering of $820 million of 8-year Senior Notes

Retrieved on:

星期二, 四月 16, 2024

Debt-to-GDP ratio, Sale, Prospectus, Person, Offering, ABL, Investment, Nature, RCF, EEA, Finance, FSMA, Environment, Amend, Vallourec, Order, Financial services, PGE, Security (finance)

Meudon (France), April 16, 2024 – Vallourec, a world leader in premium tubular solutions, announces today the launch of an offering of its Senior Notes due 2032 (the “Notes”) in an aggregate principal amount of $820 million (the “Offering”).

Key Points:

Meudon (France), April 16, 2024 – Vallourec, a world leader in premium tubular solutions, announces today the launch of an offering of its Senior Notes due 2032 (the “Notes”) in an aggregate principal amount of $820 million (the “Offering”).
This press release is not an offer of securities for sale in the United States.
This announcement does not constitute a prospectus within the meaning of the Prospectus Regulation or an offer to the public.
This announcement does not constitute a prospectus within the meaning of the UK Prospectus Regulation or an offer to the public.

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on:

星期一, 四月 15, 2024

American Academy, University, Participation, MD, Publication, Patient, RMS, AAN, USF, Mount Sinai Hospital, Multiple sclerosis, Therapy, Pharmaceutical industry

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.

Key Points:

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
A link to the data presented yesterday is included below.
Two additional presentations will be shared on Wednesday April 17, 2024.
Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The ULTIMATE I & II Phase 3 trials demonstrated robust clinical activity for BRIUMVI compared to teriflunomide and these post-hoc analyses provide interesting new insights and support BRIUMVI’s utility as an important treatment option for patients with relapsing forms of multiple sclerosis.

OCC Announces Director Elections at Annual Stockholder Meeting

Retrieved on:

星期三, 五月 1, 2024

Banking, Fintech, Professional Services, Finance, Credit Suisse, New York Stock Exchange, Intercontinental Exchange, Cboe Global Markets, General counsel, Product innovation, Exchange, Founding, Senior, Multimedia, OCC

In addition, OCC announced the election of Andrej Bolkovic , OCC Chief Executive Officer, as the Management Director.

Key Points:

In addition, OCC announced the election of Andrej Bolkovic , OCC Chief Executive Officer, as the Management Director.
The vote took place during OCC’s annual stockholder meeting on April 19, 2024.
The following Director was unanimously elected as a Class III Public Director for the term ending in 2027:
Dr. Thomas R. Cardello , Founding Member, Venice Financial Management, LLC.
“The high caliber of leadership represented on our Board demonstrates that OCC has the capabilities necessary to achieve our objectives while fulfilling our critical obligations.”

ICON Announces Pricing of USD 2 Billion Notes

Retrieved on:

星期二, 四月 30, 2024

ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).

Key Points:

ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).
The offering is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, including the Notes.
With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 102 locations in 54 countries as at March 31, 2024.

Terra Balcanica Provides Exploration Activities Update on High Grade Silver and Gold Targets at Viogor Zanik Project in Bosnia

Retrieved on:

星期四, 四月 11, 2024

Phase, ZN, Silver, Fe, News, TERA, ENE, QA/QC, Magnetism, Gold, EM, PB, National instrument, Anomaly, Sase, NW, FRA, Rare-earth element

The Company completed approximately 2,200 m of drilling along a shallow, high grade, silver-dominated, intermediate sulfidation polymetallic Ag-Au-Pb-Zn-Sb vein system at the locality known as Chumavichi (Figures 1 and 2).

Key Points:

The Company completed approximately 2,200 m of drilling along a shallow, high grade, silver-dominated, intermediate sulfidation polymetallic Ag-Au-Pb-Zn-Sb vein system at the locality known as Chumavichi (Figures 1 and 2).
The Company completed approximately 1,200 m of diamond drilling at Brezani with additional assays to be released shortly.
Figure 1 Geological map of the Viogor-Zanik project illustrating the drilled targets during the Phase II campaign.
It passes through a break in the magnetics, which is further evidence of structural control (click here to view image).

Quinbrook Closes £120m Milestone Project Financing for Five Synchronous Condenser Projects

Retrieved on:

星期四, 四月 25, 2024

Environment, Finance, Consulting, Utilities, Professional Services, Alternative Energy, Sustainability, Green Technology, Energy, National Grid, Partnership, Siemens Financial Services, Rassau, NatWest, Renewable energy

Quinbrook Infrastructure Partners (“Quinbrook”), a specialist global investment manager focused exclusively on the infrastructure needed for the energy transition, today announced it has closed £120 million in new debt financing for a portfolio of five synchronous condenser projects.

Key Points:

Quinbrook Infrastructure Partners (“Quinbrook”), a specialist global investment manager focused exclusively on the infrastructure needed for the energy transition, today announced it has closed £120 million in new debt financing for a portfolio of five synchronous condenser projects.
This is the first portfolio financing of synchronous condensers that were awarded contracts in Phases I and II of National Grid’s Stability Pathfinder Programme.
Included in this portfolio financing is Quinbrook’s first synchronous condenser, located at Rassau in Wales.
This first project was awarded a contract by National Grid in Phase I and has exceeded all operational targets since completion in 2022.